Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.

about

Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.The role of Cediranib in ovarian cancer.

P2860

Q48352556-3DFC753B-995B-491A-B9EB-BD4820C8D3B7 Q49966031-F6777F6B-E0B1-4080-A84D-B48EEA375037

P2860

Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.

Item

http://www.wikidata.org/entity/Q50885562

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Population pharmacokinetic and ...... udies in patients with cancer.

@en

Population pharmacokinetic and exposure simulation analysis for cediranib

@nl

type

Item

label

Population pharmacokinetic and ...... udies in patients with cancer.

@en

Population pharmacokinetic and exposure simulation analysis for cediranib

@nl

prefLabel

Population pharmacokinetic and ...... udies in patients with cancer.

@en

Population pharmacokinetic and exposure simulation analysis for cediranib

@nl

P1476

Population pharmacokinetic and ...... udies in patients with cancer.

@en

P2093

Anja Henningsson

http://www.w3.org/2001/XMLSchema#string

Eric Masson

http://www.w3.org/2001/XMLSchema#string

Jianguo Li

http://www.w3.org/2001/XMLSchema#string

Nidal Al-Huniti

http://www.w3.org/2001/XMLSchema#string

Weifeng Tang

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical epidemiology of epithelial ovarian cancer in the UK

Structural determinants of growth factor binding and specificity by VEGF receptor 2

Cancer statistics, 2014

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the Nati

The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming.

Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

P304

1723-1733

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13266

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28213941

http://www.w3.org/2001/XMLSchema#string

P932

5510068

http://www.w3.org/2001/XMLSchema#string

Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.

about

P2860

P2860

Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932